Concepts (229)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Randomized Controlled Trials as Topic | 16 | 2021 | 10649 | 0.69 | Why? |
| Critical Care | 9 | 2021 | 14081 | 0.67 | Why? |
| Canada | 9 | 2021 | 6018 | 0.61 | Why? |
| Sepsis | 5 | 2018 | 3517 | 0.58 | Why? |
| Antibiotic Prophylaxis | 1 | 2017 | 399 | 0.54 | Why? |
| Cardiac Surgical Procedures | 2 | 2018 | 1931 | 0.53 | Why? |
| Evidence-Based Medicine | 5 | 2020 | 3228 | 0.47 | Why? |
| Pediatricians | 1 | 2017 | 401 | 0.47 | Why? |
| Critical Illness | 10 | 2021 | 17281 | 0.45 | Why? |
| Cross Infection | 3 | 2018 | 8675 | 0.43 | Why? |
| Research Design | 4 | 2021 | 5830 | 0.42 | Why? |
| Ferritins | 1 | 2018 | 2055 | 0.38 | Why? |
| Health Equity | 1 | 2021 | 1223 | 0.38 | Why? |
| Decontamination | 1 | 2017 | 1196 | 0.34 | Why? |
| Interleukin-6 | 2 | 2021 | 7522 | 0.31 | Why? |
| Nurses | 1 | 2021 | 2285 | 0.29 | Why? |
| Respiration, Artificial | 11 | 2021 | 22116 | 0.28 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 9335 | 0.28 | Why? |
| Intensive Care Units, Pediatric | 3 | 2020 | 1098 | 0.26 | Why? |
| Heparin | 3 | 2021 | 2600 | 0.26 | Why? |
| Vasoconstrictor Agents | 2 | 2017 | 714 | 0.25 | Why? |
| Hemorrhagic Fever, Ebola | 3 | 2019 | 1475 | 0.25 | Why? |
| Glucocorticoids | 5 | 2021 | 4431 | 0.24 | Why? |
| Clinical Trials as Topic | 2 | 2021 | 7330 | 0.24 | Why? |
| Organ Dysfunction Scores | 2 | 2018 | 1475 | 0.23 | Why? |
| Pandemics | 28 | 2021 | 389249 | 0.23 | Why? |
| Child | 13 | 2021 | 70012 | 0.23 | Why? |
| Antiviral Agents | 10 | 2021 | 41703 | 0.23 | Why? |
| Pneumonia, Viral | 17 | 2020 | 243684 | 0.23 | Why? |
| Therapeutic Equipoise | 1 | 2021 | 52 | 0.22 | Why? |
| Coronavirus Infections | 17 | 2020 | 253789 | 0.22 | Why? |
| Pediatrics | 1 | 2017 | 2969 | 0.22 | Why? |
| Adrenal Cortex Hormones | 5 | 2021 | 6537 | 0.22 | Why? |
| Physicians | 1 | 2020 | 4214 | 0.22 | Why? |
| Coronavirus | 2 | 2020 | 18339 | 0.22 | Why? |
| Severity of Illness Index | 8 | 2021 | 48226 | 0.21 | Why? |
| Humans | 63 | 2021 | 930598 | 0.20 | Why? |
| Carrageenan | 1 | 2021 | 123 | 0.20 | Why? |
| Lung Compliance | 1 | 2021 | 243 | 0.20 | Why? |
| Lopinavir | 4 | 2021 | 4308 | 0.19 | Why? |
| Sample Size | 1 | 2021 | 518 | 0.19 | Why? |
| Intensive Care Units | 9 | 2021 | 29594 | 0.18 | Why? |
| Postoperative Complications | 1 | 2017 | 5861 | 0.18 | Why? |
| Cloud Computing | 1 | 2020 | 214 | 0.18 | Why? |
| Shock, Traumatic | 1 | 2017 | 18 | 0.18 | Why? |
| Capacity Building | 2 | 2021 | 683 | 0.18 | Why? |
| Practice Patterns, Physicians' | 1 | 2017 | 4927 | 0.18 | Why? |
| Ritonavir | 3 | 2021 | 4212 | 0.17 | Why? |
| Interferon beta-1a | 1 | 2020 | 316 | 0.17 | Why? |
| Dopamine | 1 | 2018 | 123 | 0.17 | Why? |
| Influenza, Human | 2 | 2020 | 10779 | 0.17 | Why? |
| Sodium Chloride, Dietary | 1 | 2016 | 62 | 0.16 | Why? |
| Post-Exposure Prophylaxis | 1 | 2021 | 472 | 0.16 | Why? |
| Dietary Fats | 1 | 2016 | 96 | 0.16 | Why? |
| Shock, Hemorrhagic | 1 | 2017 | 81 | 0.16 | Why? |
| Hydrocortisone | 3 | 2020 | 1790 | 0.15 | Why? |
| Fluid Therapy | 2 | 2017 | 628 | 0.15 | Why? |
| Angiotensin II Type 1 Receptor Blockers | 1 | 2020 | 520 | 0.15 | Why? |
| Resuscitation | 2 | 2017 | 638 | 0.14 | Why? |
| Hydroxychloroquine | 5 | 2021 | 12447 | 0.14 | Why? |
| Dexamethasone | 3 | 2020 | 2055 | 0.14 | Why? |
| Ebolavirus | 2 | 2019 | 834 | 0.14 | Why? |
| Epinephrine | 1 | 2017 | 323 | 0.14 | Why? |
| Bayes Theorem | 2 | 2021 | 3237 | 0.14 | Why? |
| Adenosine Monophosphate | 3 | 2020 | 5652 | 0.14 | Why? |
| Thrombosis | 3 | 2021 | 7504 | 0.14 | Why? |
| Alanine | 3 | 2020 | 5687 | 0.14 | Why? |
| Drug Resistance, Bacterial | 2 | 2021 | 1414 | 0.14 | Why? |
| Mycoses | 1 | 2020 | 589 | 0.13 | Why? |
| Betacoronavirus | 14 | 2020 | 204454 | 0.13 | Why? |
| Mentors | 1 | 2017 | 372 | 0.13 | Why? |
| Global Health | 3 | 2021 | 13911 | 0.12 | Why? |
| Receptors, Interleukin-6 | 1 | 2021 | 1383 | 0.12 | Why? |
| Hospitalization | 5 | 2021 | 54280 | 0.12 | Why? |
| Government Regulation | 1 | 2020 | 842 | 0.12 | Why? |
| Drug Resistance, Microbial | 1 | 2017 | 419 | 0.12 | Why? |
| Iron | 1 | 2018 | 619 | 0.12 | Why? |
| Surge Capacity | 1 | 2020 | 894 | 0.12 | Why? |
| Hospital Bed Capacity | 1 | 2020 | 1300 | 0.12 | Why? |
| Brain Injuries | 1 | 2017 | 374 | 0.11 | Why? |
| Plasma | 2 | 2020 | 1809 | 0.11 | Why? |
| Ivermectin | 1 | 2021 | 973 | 0.11 | Why? |
| Anticoagulants | 3 | 2021 | 9563 | 0.11 | Why? |
| International Cooperation | 2 | 2021 | 3436 | 0.11 | Why? |
| Anti-Bacterial Agents | 5 | 2021 | 10083 | 0.11 | Why? |
| Trust | 1 | 2021 | 1487 | 0.10 | Why? |
| Drug Combinations | 4 | 2021 | 3852 | 0.10 | Why? |
| Drug Approval | 1 | 2020 | 1325 | 0.10 | Why? |
| Age Distribution | 1 | 2020 | 3567 | 0.10 | Why? |
| Public Opinion | 1 | 2020 | 1165 | 0.10 | Why? |
| Prenatal Care | 1 | 2021 | 1314 | 0.10 | Why? |
| Dyslipidemias | 1 | 2016 | 791 | 0.10 | Why? |
| Perception | 1 | 2021 | 2827 | 0.10 | Why? |
| Hospital Mortality | 7 | 2021 | 22087 | 0.10 | Why? |
| Gastrointestinal Tract | 1 | 2017 | 1113 | 0.09 | Why? |
| Health Care Costs | 1 | 2017 | 1007 | 0.09 | Why? |
| Length of Stay | 3 | 2020 | 11042 | 0.09 | Why? |
| Self Report | 1 | 2020 | 3802 | 0.09 | Why? |
| Network Meta-Analysis | 2 | 2020 | 426 | 0.09 | Why? |
| Multiple Organ Failure | 1 | 2018 | 1724 | 0.09 | Why? |
| Developing Countries | 3 | 2020 | 4283 | 0.09 | Why? |
| Community-Acquired Infections | 1 | 2020 | 2328 | 0.09 | Why? |
| Respiratory Insufficiency | 2 | 2020 | 7301 | 0.09 | Why? |
| Research | 1 | 2020 | 2115 | 0.09 | Why? |
| Adult | 15 | 2021 | 244371 | 0.09 | Why? |
| Aerosols | 2 | 2021 | 5393 | 0.09 | Why? |
| Leadership | 1 | 2021 | 2241 | 0.08 | Why? |
| Research Personnel | 1 | 2017 | 1037 | 0.08 | Why? |
| Public Health Surveillance | 1 | 2021 | 3129 | 0.08 | Why? |
| Attitude to Health | 1 | 2020 | 2002 | 0.08 | Why? |
| Africa, Western | 2 | 2018 | 363 | 0.08 | Why? |
| Female | 19 | 2021 | 380317 | 0.08 | Why? |
| Oxygen Inhalation Therapy | 1 | 2020 | 3629 | 0.08 | Why? |
| Cross-Sectional Studies | 4 | 2021 | 53120 | 0.08 | Why? |
| Male | 17 | 2021 | 367725 | 0.08 | Why? |
| Chloroquine | 1 | 2021 | 3152 | 0.08 | Why? |
| Disease Management | 2 | 2021 | 6841 | 0.07 | Why? |
| Practice Guidelines as Topic | 5 | 2021 | 15421 | 0.07 | Why? |
| Disease Progression | 2 | 2021 | 13580 | 0.07 | Why? |
| Odds Ratio | 3 | 2021 | 5861 | 0.07 | Why? |
| Pregnancy Complications, Infectious | 2 | 2021 | 11559 | 0.07 | Why? |
| Treatment Failure | 2 | 2021 | 2106 | 0.07 | Why? |
| Noninvasive Ventilation | 1 | 2018 | 2329 | 0.07 | Why? |
| Infant | 4 | 2020 | 30274 | 0.07 | Why? |
| Intubation, Intratracheal | 1 | 2020 | 3962 | 0.07 | Why? |
| Pregnancy | 3 | 2021 | 23879 | 0.07 | Why? |
| Feeding Behavior | 1 | 2016 | 1909 | 0.07 | Why? |
| Mortality | 1 | 2021 | 7132 | 0.07 | Why? |
| Health Resources | 1 | 2017 | 2592 | 0.06 | Why? |
| Registries | 2 | 2020 | 12327 | 0.06 | Why? |
| Biomedical Research | 2 | 2021 | 5270 | 0.06 | Why? |
| Child, Preschool | 4 | 2020 | 36283 | 0.06 | Why? |
| Health Behavior | 1 | 2020 | 4449 | 0.06 | Why? |
| Comorbidity | 3 | 2021 | 34796 | 0.06 | Why? |
| Treatment Outcome | 7 | 2021 | 51732 | 0.06 | Why? |
| Surveys and Questionnaires | 2 | 2021 | 43792 | 0.06 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.06 | Why? |
| Middle Aged | 12 | 2021 | 270681 | 0.05 | Why? |
| Adolescent | 6 | 2021 | 86841 | 0.05 | Why? |
| Pneumonia | 1 | 2020 | 5652 | 0.05 | Why? |
| Observational Studies as Topic | 2 | 2018 | 1887 | 0.05 | Why? |
| Databases, Factual | 3 | 2020 | 6248 | 0.05 | Why? |
| Amodiaquine | 1 | 2019 | 57 | 0.05 | Why? |
| Aged | 9 | 2021 | 215776 | 0.05 | Why? |
| Disease Outbreaks | 2 | 2018 | 27595 | 0.05 | Why? |
| Methylprednisolone | 2 | 2020 | 2107 | 0.05 | Why? |
| Pragmatic Clinical Trials as Topic | 1 | 2020 | 350 | 0.05 | Why? |
| Hemorrhage | 2 | 2021 | 3013 | 0.05 | Why? |
| Intention to Treat Analysis | 1 | 2020 | 673 | 0.05 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.05 | Why? |
| Television | 1 | 2020 | 224 | 0.05 | Why? |
| Epidemiologic Studies | 1 | 2021 | 554 | 0.05 | Why? |
| Incidence | 1 | 2021 | 25622 | 0.05 | Why? |
| Patient Acceptance of Health Care | 1 | 2017 | 5002 | 0.05 | Why? |
| APACHE | 1 | 2020 | 682 | 0.04 | Why? |
| Survival Analysis | 2 | 2021 | 7592 | 0.04 | Why? |
| Early Termination of Clinical Trials | 1 | 2020 | 1256 | 0.04 | Why? |
| Young Adult | 4 | 2021 | 93724 | 0.04 | Why? |
| Drug Therapy, Combination | 2 | 2021 | 7268 | 0.04 | Why? |
| Artemisinins | 1 | 2019 | 238 | 0.04 | Why? |
| Cause of Death | 2 | 2021 | 4823 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.04 | Why? |
| Chemoprevention | 1 | 2021 | 585 | 0.04 | Why? |
| Emergency Service, Hospital | 1 | 2021 | 14232 | 0.04 | Why? |
| Logistic Models | 2 | 2021 | 9089 | 0.04 | Why? |
| Group Processes | 1 | 2017 | 210 | 0.04 | Why? |
| Intubation | 1 | 2018 | 437 | 0.04 | Why? |
| Prospective Studies | 4 | 2021 | 43301 | 0.04 | Why? |
| Hypertension | 1 | 2016 | 8895 | 0.04 | Why? |
| Cannula | 1 | 2020 | 750 | 0.03 | Why? |
| Drug Resistance | 1 | 2017 | 395 | 0.03 | Why? |
| North America | 1 | 2018 | 1400 | 0.03 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 8811 | 0.03 | Why? |
| Patient Participation | 1 | 2021 | 829 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2020 | 2437 | 0.03 | Why? |
| Standard of Care | 1 | 2020 | 1297 | 0.03 | Why? |
| Global Burden of Disease | 1 | 2017 | 531 | 0.03 | Why? |
| Shock | 1 | 2020 | 1868 | 0.03 | Why? |
| Airway Extubation | 1 | 2018 | 403 | 0.03 | Why? |
| Pakistan | 1 | 2020 | 2302 | 0.03 | Why? |
| Oropharynx | 1 | 2021 | 1581 | 0.03 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2021 | 1731 | 0.03 | Why? |
| Risk Factors | 2 | 2018 | 71621 | 0.03 | Why? |
| Delivery of Health Care | 1 | 2018 | 15909 | 0.03 | Why? |
| False Negative Reactions | 1 | 2018 | 1785 | 0.03 | Why? |
| Combined Modality Therapy | 1 | 2021 | 3395 | 0.03 | Why? |
| Data Collection | 1 | 2020 | 1769 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2020 | 4260 | 0.03 | Why? |
| Area Under Curve | 1 | 2018 | 2564 | 0.03 | Why? |
| Dose-Response Relationship, Drug | 1 | 2020 | 3776 | 0.03 | Why? |
| Aged, 80 and over | 1 | 2021 | 88759 | 0.03 | Why? |
| Uncertainty | 1 | 2021 | 1888 | 0.02 | Why? |
| Anti-Infective Agents | 1 | 2021 | 1766 | 0.02 | Why? |
| Health Facilities | 1 | 2017 | 1230 | 0.02 | Why? |
| Pain Management | 1 | 2017 | 854 | 0.02 | Why? |
| Pyrazines | 1 | 2019 | 1783 | 0.02 | Why? |
| Amides | 1 | 2019 | 1864 | 0.02 | Why? |
| Epidemiological Monitoring | 1 | 2020 | 3493 | 0.02 | Why? |
| Australia | 1 | 2020 | 6306 | 0.02 | Why? |
| Guideline Adherence | 1 | 2020 | 2309 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2017 | 2259 | 0.02 | Why? |
| Point-of-Care Systems | 1 | 2020 | 2955 | 0.02 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.02 | Why? |
| Monitoring, Physiologic | 1 | 2017 | 1956 | 0.02 | Why? |
| Infant, Newborn | 2 | 2018 | 23105 | 0.02 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.02 | Why? |
| Poverty | 1 | 2018 | 2302 | 0.02 | Why? |
| Risk | 1 | 2018 | 5288 | 0.02 | Why? |
| Quality of Health Care | 1 | 2017 | 1948 | 0.02 | Why? |
| Pilot Projects | 1 | 2016 | 5182 | 0.02 | Why? |
| Information Dissemination | 1 | 2020 | 2986 | 0.02 | Why? |
| Immunization, Passive | 1 | 2021 | 10067 | 0.02 | Why? |
| Risk Assessment | 2 | 2018 | 25439 | 0.02 | Why? |
| Europe | 1 | 2021 | 12702 | 0.02 | Why? |
| Nasopharynx | 1 | 2021 | 10224 | 0.01 | Why? |
| Coinfection | 1 | 2021 | 6820 | 0.01 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 6653 | 0.01 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 3832 | 0.01 | Why? |
| Antibodies, Monoclonal | 1 | 2019 | 8041 | 0.01 | Why? |
| India | 1 | 2016 | 11875 | 0.01 | Why? |
| Social Media | 1 | 2020 | 5798 | 0.01 | Why? |
| Retrospective Studies | 2 | 2021 | 105322 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2018 | 22971 | 0.01 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| United States | 1 | 2020 | 46150 | 0.01 | Why? |
| Infection Control | 1 | 2021 | 23131 | 0.01 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.01 | Why? |